About us


Brexit and the pharmaceutical sector

Brexit and the pharmaceutical sector

The UK’s withdrawal from the EU entered into force on 1 February 2020. With the entry into force of the withdrawal agreement, a transition period began until the end of 2020. During this time, the EU’s current rules remained in force and the future relationship was negotiated. The UK’s withdrawal from the EU entered into force on 1 January 2021.

On 24.12.2020 the EU and the UK concluded their negotiations on the Trade and Cooperation Agreement (TCA) and the complementary agreements on security of classified information and nuclear cooperation.

Agreements and more information | European Commission

Read more:

Information about Brexit (Prime Minister's Office) 

Information about Brexit (Ministry of Social Affairs and Health)

Information about Brexit (EMA)

Brexit-related guidance for companies (EMA)

European authorities working to avoid shortages of medicines due to Brexit – questions and answers (EMA 31.1.2020)


Medicines cannot be purchased from Great Britain by mail starting from 1 January 2021

Guidelines for when the Brexit transition period ends on 31 December 2020

Common guidelines from the Commission to prevent problems in the supply of medicines

Brexit related batch control testing exemption request submissions to Fimea

Preparations for Brexit well underway in the pharmaceutical industry

Marketing Authorisation Holders should prepare for Brexit

Preparations for Brexit in social security provision and pharmaceutical service 

Background information:

How are medicines supplied to users in Finland?

Marketing Authorisations